Glucocorticoid-Induced Leucine Zipper (GILZ) Over-Expression in T Lymphocytes Inhibits Inflammation and Tissue Damage in Spinal Cord Injury

Neurotherapeutics

Volumn 9, Issue 1, 2012, Pages 210-225

  Esposito, Emanuela ^a   Bruscoli, Stefano ^b   Mazzon, Emanuela ^a   Paterniti, Irene ^a   Coppo, Maddalena ^b   Velardi, Enrico ^b   Cuzzocrea, Salvatore ^a   Riccardi, Carlo ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

apoptosis; Glucocorticoid induced leucine zipper; glucocorticoids; inflammation; spinal cord injury; T lymphocytes

Indexed keywords

GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LEUCINE ZIPPER PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; IMMUNE RESPONSE; INFLAMMATION; MOUSE; NERVOUS TISSUE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD INJURY; T LYMPHOCYTE; TISSUE INJURY;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CYCLIN D1; CYTOKINES; DINOPROSTONE; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; IN SITU NICK-END LABELING; INFLAMMATION; MICE; MICE, TRANSGENIC; NITRIC OXIDE SYNTHASE TYPE II; PEROXIDASE; SIGNAL TRANSDUCTION; SPINAL CORD INJURIES; T-LYMPHOCYTES; TRANSCRIPTION FACTORS;

EID: 84856575653     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-011-0084-7     Document Type: Article

References (47)

1. Malmberg AB, Yaksh TL. Cyclooxygenase inhibition and the spinal release of prostaglandin E2 and amino acids evoked by paw formalin injection: a microdialysis study in unanesthetized rats. J Neurosci 1995; 15: 2768-2776.
2. Bartholdi D, Schwab ME. Methylprednisolone inhibits early inflammatory processes but not ischemic cell death after experimental spinal cord lesion in the rat. Brain Res 1995; 672: 177-186.
3. Amar AP, Levy ML. Pathogenesis and pharmacological strategies for mitigating secondary damage in acute spinal cord injury. Neurosurgery 1999; 44: 1027-1040.
4. Carlson SL, Parrish ME, Springer JE, Doty K, Dossett L. Acute inflammatory response in spinal cord following impact injury. Exp Neurol 1998; 151: 77-88.
5. de Castro R Jr, Hughes MG, Xu GY, et al. Evidence that infiltrating neutrophils do not release reactive oxygen species in the site of spinal cord injury. Exp Neurol 2004; 190: 414-424.
6. Gomez-Nicola D, Valle-Argos B, Suardiaz M, Taylor JS, Nieto-Sampedro M. Role of IL-15 in spinal cord and sciatic nerve after chronic constriction injury: regulation of macrophage and T-cell infiltration. J Neurochem 2008; 107: 1741-1752.
7. Popovich PG, Wei P, Stokes BT. Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J Comp Neurol 1997; 377: 443-464.
8. Profyris C, Cheema SS, Zang D, Azari MF, Boyle K, Petratos S. Degenerative and regenerative mechanisms governing spinal cord injury. Neurobiol Dis 2004; 15: 415-436.
9. Bracken MB, Shepard MJ, Holford TR, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997; 277: 1597-1604.
10. Hall ED. Antioxidant therapies for acute spinal cord injury. Neurotherapeutics 2011; 8: 152-167.
11. Lee JM, Yan P, Xiao Q et al. Methylprednisolone protects oligodendrocytes but not neurons after spinal cord injury. J Neurosci 2008; 28: 3141-3149.
12. Pott Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 2008; 131(pt 7): 1880-1894.
13. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-1723.
14. Riccardi C, Bruscoli S, Migliorati G. Molecular mechanisms of immunomodulatory activity of glucocorticoids. Pharmacol Res 2002; 45: 361-368.
15. D'Adamio F, Zollo O, Moraca R et al. A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity 1997; 7: 803-812.
16. Riccardi C, Bruscoli S, Ayroldi E, Agostini M, Migliorati G. GILZ, a glucocorticoid hormone induced gene, modulates T lymphocytes activation and death through interaction with NF-kB. Adv Exp Med Biol 2001; 495: 31-39.
17. Ayroldi E, Migliorati G, Bruscoli S et al. Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor kappa B. Blood 2001; 98: 743-753.
18. Berrebi D, Bruscoli S, Cohen N et al. Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10. Blood 2003; 101: 29-738.
19. Bruscoli S, Donato V, Velardi E et al. Glucocorticoid-induced leucine zipper (GILZ) and long GILZ inhibit myogenic differentiation and mediate anti-myogenic effects of glucocorticoids. J Biol Chem 2010; 285: 10385-10396.
20. Cannarile L, Cuzzocrea S, Santucci L et al. Glucocorticoid-induced leucine zipper is protective in Th1-mediated models of colitis. Gastroenterology 2009; 136: 530-541.
21. Di Marco B, Massetti M, Bruscoli S et al. Glucocorticoid-induced leucine zipper (GILZ)/NF-kappaB interaction: role of GILZ homo-dimerization and C-terminal domain. Nucleic Acids Res 2007; 35: 517-528.
22. Ayroldi E, Zollo O, Bastianelli A et al. GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signaling. J Clin Invest 2007; 117: 1605-1615.
23. Ayroldi E, Riccardi C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J 2009; 23: 3649-3658.
24. Cannarile L, Fallarino F, Agostini M et al. Increased GILZ expression in transgenic mice up-regulates Th-2 lymphokines. Blood 2006; 107: 1039-1047.
25. Delfino DV, Agostini M, Spinicelli S, Vito P, Riccardi C. Decrease of Bcl-xL and augmentation of thymocyte apoptosis in GILZ overexpressing transgenic mice. Blood 2004; 104: 4134-4141.
26. Genovese T, Rossi A, Mazzon E et al. Effects of zileuton and montelukast in mouse experimental spinal cord injury. Br J Pharmacol 2008; 153: 568-582.
27. Bethea JR, Castro M, Keane RW, Lee TT, Dietrich WD, Yezierski RP. Traumatic spinal cord injury induces nuclear factor-kappaB activation. J Neurosci 1998; 18: 3251-3260.
28. Shea TB. Technical report. An inexpensive densitometric analysis system using a Macintosh computer and a desktop scanner. Biotechniques 1994; 16: 1126-1128.
29. Ceruti S, Villa G, Genovese T, et al. The P2Y-like receptor GPR17 as a sensor of damage and a new potential target in spinal cord injury. Brain 2009; 132(Pt 8): 2206-2218.
30. McAndrew J, Patel RP, Jo H, et al. The interplay of nitric oxide and peroxynitrite with signal transduction pathways: implications for disease. Semin Perinatol 1997; 21: 351-366.
31. Xu J, Kim GM, Chen S et al. iNOS and nitrotyrosine expression after spinal cord injury. J Neurotrauma 2001; 18: 523-532.
32. Bal-Price A, Brown GC. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci 2001; 21: 6480-6491.
33. Madrigal JL, Moro MA, Lizasoain I et al. Inducible nitric oxide synthase expression in brain cortex after acute restraint stress is regulated by nuclear factor kappaB-mediated mechanisms. J Neurochem 2001; 76: 532-538.
34. La Rosa G, Cardali S, Genovese T, et al. Inhibition of the nuclear factor-kappaB activation with pyrrolidine dithiocarbamate attenuating inflammation and oxidative stress after experimental spinal cord trauma in rats. J Neurosurg Spine 2004; 1: 311-321.
35. Fleming JC, Norenberg MD, Ramsay DA et al. The cellular inflammatory response in human spinal cords after injury. Brain 2006; 129(Pt 12): 3249-3269.
36. Vanegas H, Schaible HG. Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord. Prog Neurobiol, 64(4), 327-363 (2001).
37. Beaulieu E, Ngo D, Santos L et al. Glucocorticoid-induced leucine zipper is an endogenous antiinflammatory mediator in arthritis. Arthritis Rheum 2010; 62: 2651-2661.
38. Yang N, Zhang W, Shi XM. Glucocorticoid-induced leucine zipper (GILZ) mediates glucocorticoid action and inhibits inflammatory cytokine-induced COX-2 expression. J Cell Biochem 2008; 103: 1760-1771.
39. Verma IM. Nuclear factor (NF)-kappaB proteins: therapeutic targets. Ann Rheum Dis 2004; 63(suppl 2): ii57-ii61.
40. Schwab ME, Bartholdi D. Degeneration and regeneration of axons in the lesioned spinal cord. Physiol Rev 1996; 76: 319-370.
41. Ahn YH, Lee G, Kang SK. Molecular insights of the injured lesions of rat spinal cords: Inflammation, apoptosis, and cell survival. Biochem Biophys Res Commun 2006; 348: 560-570.
42. Esposito E, Cuzzocrea S. Anti-TNF therapy in the injured spinal cord. Trends Pharmacol Sci 2011; 32: 107-115.
43. Nakamura M, Okada S, Toyama Y, Okano H. Role of IL-6 in spinal cord injury in a mouse model. Clin Rev Allergy Immunol 2005; 28: 197-204.
44. Cantarella G, Di Benedetto G, Scollo M et al. Neutralization of tumor necrosis factor-related apoptosis-inducing ligand reduces spinal cord injury damage in mice. Neuropsychopharmacology 2010; 35: 1302-1314.
45. Kwon BK, Tetzlaff W, Grauer JN, Beiner J, Vaccaro AR. Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J 2004; 4: 451-464.
46. Nesic O, Xu GY, McAdoo D, High KW, Hulsebosch C, Perez-Pol R. IL-1 receptor antagonist prevents apoptosis and caspase-3 activation after spinal cord injury. J Neurotrauma 2001; 18: 947-956.
47. Dong H, Fazzaro A, Xiang C, Korsmeyer SJ, Jacquin MF, McDonald JW. Enhanced oligodendrocyte survival after spinal cord injury in Bax-deficient mice and mice with delayed Wallerian degeneration. J Neurosci 2003; 23: 8682-8691.